Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
APR-246 (Eprenetapopt/PRIMA-1Met) is a very potent anti-cancer drug in clinical trials and was initially developed as a p53 refolding agent. As an alternative mode of action, the elevation of reactive oxygen species (ROS) has been proposed. Through an in silico analysis, we investigated the responses of approximately 800 cancer cell lines (50 entities; Cancer Therapeutics Response Portal, CTRP) to APR-246 treatment. In particular, neuroblastoma, lymphoma and acute lymphocytic leukemia cells were highly responsive. With gene expression data from the Cancer Cell Line Encyclopedia (CCLE; n = 883) and patient samples (n = 1643) from the INFORM registry study, we confirmed that these entities express low levels of SLC7A11, a previously described predictive biomarker for APR-246 responsiveness. Combining the CTRP drug response data with the respective CCLE gene expression profiles, we defined a novel gene signature, predicting the effectiveness of APR-246 treatment with a sensitivity of 90% and a specificity of 94%. We confirmed the predicted APR-246 sensitivity in 8/10 cell lines and in ex vivo cultures of patient samples. Moreover, the combination of ROS detoxification-impeding APR-246 with approved HDAC-inhibitors, known to elevate ROS, substantially increased APR-246 sensitivity in cell cultures and in vivo in two zebrafish neuroblastoma xenograft models. These data provide evidence that APR-246, in combination with HDAC-inhibitors, displays a novel potent targeted treatment option for neuroblastoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibits the growth of p53 mutant tumors of various origins in combination with other anticancer drugs.390–396”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [392]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“This restores its DNA-binding function and induces a strong apoptotic signal [15,17].”
BackgroundHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“In the next step, we applied the identified gene signature to all cell lines in the CCLE with available sensitivity data and chose the maximum APR-246 plasma trough level of 20 μM as the sensitivity threshold to be predicted [12].”
MethodHistone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · cited 1×
“Western blot analysis was performed as previously described [28].”
MethodSelf-citationInhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321
Orthotopic patient-derived xenografts of paediatric solid tumours
Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., et al. (2017) · Nature · doi:10.1038/nature23647 · Cited by 286
Research works printed but not linked: 51
- Brodeur, 2003, Neuroblastoma: Biological insights into a clinical enigma, Nat. Rev. Cancer, 3, 203, 10.1038/nrc1014 · DOI · Paper page
- Cohn, 2009, The International Neuroblastoma Risk Group (INRG) classification system: An INRG task force report, J. Clin. Oncol., 27, 289, 10.1200/JCO.2008.16.6785 · DOI · Paper page
- Monclair, 2009, The International Neuroblastoma Risk Group (INRG) staging system: An INRG task force report, J. Clin. Oncol., 27, 298, 10.1200/JCO.2008.16.6876 · DOI · Paper page
- Wasylishen, A.R., and Lozano, G. (2016). Attenuating the p53 pathway in human cancers: Many means to the same end. Cold Spring Harb Perspect. Med., 6. · DOI · Paper page
- Ackermann, 2018, A mechanistic classification of clinical phenotypes in neuroblastoma, Science, 362, 1165, 10.1126/science.aat6768 · DOI · Paper page
- Tweddle, 2001, p53 cellular localization and function in neuroblastoma: Evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells, Am. J. Pathol., 158, 2067, 10.1016/S0002-9440(10)64678-0 · doi:10.1016/s0002-9440(10)64678-0
- Isaacs, 1998, Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines, Cell Growth Differ., 9, 545
- Moll, 1995, Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors, Proc. Natl. Acad. Sci. USA, 92, 4407, 10.1073/pnas.92.10.4407 · DOI · Paper page
- Duffy, 2017, Mutant p53 as a target for cancer treatment, Eur. J. Cancer, 83, 258, 10.1016/j.ejca.2017.06.023 · DOI · Paper page
- Storz, 2005, Reactive oxygen species in tumor progression, Front. Biosci., 10, 1881, 10.2741/1667 · DOI · Paper page
- Wang, 2018, An acquired vulnerability of drug-resistant melanoma with therapeutic potential, Cell, 173, 1413, 10.1016/j.cell.2018.04.012 · DOI · Paper page
- Koeneke, 2015, HDAC family members intertwined in the regulation of autophagy: A druggable vulnerability in aggressive tumor entities, Cells, 4, 135, 10.3390/cells4020135 · DOI · Paper page
- Ridinger, J., Koeneke, E., Kolbinger, F.R., Koerholz, K., Mahboobi, S., Hellweg, L., Gunkel, N., Miller, A.K., Peterziel, H., and Schmezer, P. (2018). Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. Sci. Rep., 8. · DOI
- Fabian, 2014, GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3, Cancer Res., 74, 2604, 10.1158/0008-5472.CAN-13-1904 · DOI
- Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., and Lodrini, M. (2015). Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol. Commun., 3. · DOI
- Oehme, 2013, Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas, Autophagy, 9, 2163, 10.4161/auto.26450 · DOI
- Witt, 2009, Targeting histone deacetylases in neuroblastoma, Curr. Pharm. Des., 15, 436, 10.2174/138161209787315774 · DOI
- Kolbinger, 2018, The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines, Arch. Toxicol., 92, 2649, 10.1007/s00204-018-2234-8 · DOI
- Milde, 2010, HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth, Clin. Cancer Res., 16, 3240, 10.1158/1078-0432.CCR-10-0395 · DOI · Paper page
- El-Naggar, A.M., Somasekharan, S.P., Wang, Y., Cheng, H., Negri, G.L., Pan, M., Wang, X.Q., Delaidelli, A., Rafn, B., and Cran, J. (2019). Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep., 20. · DOI
- Anastas, J.N., Zee, B.M., Kalin, J.H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M.A., Giera, S., Gillespie, S.M., and Das, J. (2019). Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell, 36. · DOI · Paper page
- Witt, 2012, Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia, Klin. Padiatr., 224, 398, 10.1055/s-0032-1323692 · doi:10.1055/s-0032-1323692
- (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 322968, Prima-1, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Prima-1.
- (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 52918385, Prima-1met, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Prima-1met.
- (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 322973, 2-Methylenequinuclidin-3-one, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/2-Methylenequinuclidin-3-one.
- Jemaà, M., Sime, W., Abassi, Y., Lasorsa, V.A., Bonne Køhler, J., Michaelis, M., Cinatl, J., Capasso, M., and Massoumi, R. (2020). Gene expression signature of acquired chemoresistance in neuroblastoma cells. Int. J. Mol. Sci., 21. · DOI
- Sapio, R.T., Nezdyur, A.N., Krevetski, M., Anikin, L., Manna, V.J., Minkovsky, N., and Pestov, D.G. (2017). Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner. Sci. Rep., 7. · DOI
- Worst, 2016, Next-generation personalized medicine for high-risk pediatric cancer patients—The INFORM pilot study, Eur. J. Cancer, 65, 91, 10.1016/j.ejca.2016.06.009 · DOI · Paper page
- Lin, 2017, A protocol for rapid post-mortem cell culture of Diffuse Intrinsic Pontine Glioma (DIPG), J. Vis. Exp., 9, 5233
- Fischer, 2005, Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA, J. Mol. Diagn., 7, 89, 10.1016/S1525-1578(10)60013-X · DOI
- Witt, 2003, Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin, Blood, 101, 2001, 10.1182/blood-2002-08-2617 · DOI · Paper page
- Wrobel, J.K., Najafi, S., Ayhan, S., Gatzweiler, C., Krunic, D., Ridinger, J., Milde, T., Westermann, F., Peterziel, H., and Meder, B. (2020). Rapid in vivo validation of HDAC inhibitor-based treatments in neuroblastoma zebrafish xenografts. Pharmaceuticals, 13. · DOI
- Aksoy, B.A., Dancík, V., Smith, K., Mazerik, J.N., Ji, Z., Gross, B., Nikolova, O., Jaber, N., Califano, A., and Schreiber, S.L. (2017). CTD2 Dashboard: A searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database, 11. · DOI
- Rees, 2016, Correlating chemical sensitivity and basal gene expression reveals mechanism of action, Nat. Chem. Biol., 12, 109, 10.1038/nchembio.1986 · DOI · Paper page
- Basu, 2013, An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, 154, 1151, 10.1016/j.cell.2013.08.003 · DOI · Paper page
- Ianevski, 2020, SynergyFinder 2.0: Visual analytics of multi-drug combination synergies, Nucleic Acids Res., 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
- Lu, 2016, PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK, Oncotarget, 7, 83017, 10.18632/oncotarget.12940 · DOI
- Aryee, 2013, Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma, Br. J. Cancer, 109, 2696, 10.1038/bjc.2013.635 · DOI
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., and Ishioka, C. (2003). Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA, 100. · DOI · Paper page
- Sultana, 2019, Zinc dependent histone deacetylase inhibitors in cancer therapeutics: Recent update, Curr. Med. Chem., 26, 7212, 10.2174/0929867325666180530094120 · DOI
- Mlakar, 2019, PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level, J. Exp. Clin. Cancer Res., 38, 69, 10.1186/s13046-019-1066-6 · DOI · Paper page
- Demir, 2020, Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia, Haematologica, 105, 170, 10.3324/haematol.2018.199364 · DOI
- Nikolaev, A., Fiveash, J.B., and Yang, E.S. (2020). Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int. J. Mol. Sci., 21. · doi:10.20944/preprints201912.0076.v1
- Urdiciain, 2021, APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells, Int. J. Oncol., 58, 312, 10.3892/ijo.2021.5177 · DOI
- van Groningen, T., Akogul, N., Westerhout, E.M., Chan, A., Hasselt, N.E., Zwijnenburg, D.A., Broekmans, M., Stroeken, P., Haneveld, F., and Hooijer, G.K.J. (2019). A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat. Commun., 10. · DOI · Paper page
- Groningen, 2017, Neuroblastoma is composed of two super-enhancer-associated differentiation states, Nat. Genet., 49, 1261, 10.1038/ng.3899 · DOI · Paper page
- Cen, J., Zhang, L., Liu, F., Zhang, F., and Ji, B.S. (2016). Long-term alteration of reactive oxygen species led to multidrug resistance in MCF-7 cells. Oxid Med. Cell Longev., 2016. · DOI
- Waghela, 2021, Upregulation of NOX-2 and Nrf-2 promotes 5-Fluorouracil resistance of human colon carcinoma (HCT-116) cells, Biochemistry, 86, 262
- Zhao, 2021, RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in chemotherapy-resistant cancers, Am. J. Cancer Res., 11, 729
- Halliwell, 2014, Cell culture, oxidative stress, and antioxidants: Avoiding pitfalls, Biomed. J., 37, 99
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I.
- Affiliations
- Hopp Children’s Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany
- Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany
- Institute for Cardiomyopathies Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-09-05
- Volume
- 13
- Issue
- 17
- Pages
- 4476
- ISSN
- 2072-6694
- Cited by
- 14
- References
- 15
- Language
- en
- Funders
- Mildred Scheel Doctoral Scholarship (70113124)
- SFB 1389-UNITE Glioblastoma (Work Package A02)
- H.W. & J. Hector Foundation (M91)
- Ministry of Rural Affairs and Consumer Protection Baden-Wuerttemberg (ID 4781)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. https://app.cochat.ai/papers/10.3390/cancers13174476
- The paper
- Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I. (2021). Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. https://doi.org/10.3390/cancers13174476
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.